NeoPharm,'DERMO REFRESH GEL'products

NeoPharm (on behalf of Prak ByeongDek) has launched a new professional nursing brand 'DERMABLE', which can inhibit or eliminate the body sweat and body odor of males.
As the age increases, the human body will secrete the so-called "old taste" and other unpleasant smell, coupled with the accumulation of nicotine and ammonia smell of long-term smoking, it will form an unpleasant smell that perfume can not cover up.
The United States and Japan have already formed a sense of body odor, which is called Smell Harassment and Aging Odor. To this end, NeoPharm launched DERMO REFRESH GEL through its professional body care brand 'DERMABLE', not to hide the body odor, but through careful research, to find out the causes of body odor and effectively remove body odor.
DERMO REFRESH GEL product has passed the clinical experiment of eliminating `Noneral'and `Nicotine' components which form the `senile flavor'. At the same time, the patented components of deodorization and the extracts of green tea, Platycladus orientalis leaves and persimmon leaves have been added to effectively inhibit body odor and clean them.
In addition, the deodorization experiments of the components of acetaminophen and formaldehyde, skin moisturizing experiments and skin protection film consolidation experiments were also carried out. As a brand of home care, NoPharm uses pure natural ingredients and never adds 11 harmful substances. It has a soft texture and can effectively remove dirt such as human secretions and cutin.
2026-10-12
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
LG Chem Enters Semiconductor Stripper Market for the First Time, Cutting Process Time by 50%
-
EU Clears Carlyle's Acquisition of BASF's Coatings Business, but Demands Divestment of Nouryon's Polysulfide Assets: What Are the Underlying Risks?
-
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
FDA Dye Phase-Out Push Opens a Bigger Window for Natural Color Solutions
-
Merck Wins Approval for the World’s First Oral PCSK9 Drug, with Potential Annual Sales of $5 Billion
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Private Equity Firm Acquires Lyons Magnus for About $1 Billion as Beverage and Nutrition Ingredients Consolidate
-
Lianolong Bets Big on Electronic Adhesives with $50M Strategic Stake in Sidofu
-
Sichuan Unveils Revised List of 14 Qualified Chemical Parks in Major Industrial Realignment
Recommend Reading
-
Moldova Proposes Stricter Quality Standards for Edible Casein and Caseinates
-
Hormuz Reopening Signal: 155 Tankers Still Waiting
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
New York Targets Additives and GRAS Disclosure
-
Supply-side Contraction, Inventory Supports Stable Price Operations
-
Business Society’s Market Outlook for Phthalic Anhydride on August 17, 2026: Continuing a Slight Rise
-
Supply Reduction, Rising Costs, DOP Price Increase
-
Business Society’s Market Outlook for Gasoline on August 17, 2026: Fluctuating Trend
-
This Week China's Titanium Dioxide Market Trended Upward (12.1-12.5)